Inhibitor of heat shock protein 90 (Hsp90) chaperone activity, and an analog of geldanamycin (Cat. No. 1368). Subsequently inhibits the activity of oncogenic proteins such as p185erbB-2 (IC50 = 31 nM), N-ras, Ki-ras and c-Akt. Antitumor in vivo. Also protects neuroprogenitor cells against stress-induced apoptosis at low concentrations (10 nM) in vitro.
|Storage||Desiccate at -20°C|
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
All Tocris products are intended for laboratory research use only.
|Solvent||Max Conc. mg/mL||Max Conc. mM|
Preparing Stock Solutions
The following data is based on the product molecular weight 585.7. Batch specific molecular weights may vary from batch to batch due to solvent of hydration, which will affect the solvent volumes required to prepare stock solutions.
|Concentration / Solvent Volume / Mass||1 mg||5 mg||10 mg|
|1 mM||1.71 mL||8.54 mL||17.07 mL|
|5 mM||0.34 mL||1.71 mL||3.41 mL|
|10 mM||0.17 mL||0.85 mL||1.71 mL|
|50 mM||0.03 mL||0.17 mL||0.34 mL|
References are publications that support the products' biological activity.
Hostein et al (2001) Inhibition of signal transduction by the Hsp90 inhibitor 17-allylamino-17-demethoxygeldanamycin results in cytostasis and apoptosis. Cancer Res. 61 4003 PMID: 11358818
Schnur et al (1995) Inhibition of the oncogene product p185erbB-2 in vitro and in vivo by geldanamycin and dihydrogeldanamycin derivatives. J.Med.Chem. 38 3806 PMID: 7562911
Yang et al (2001) Disruption of the EF-2 kinase/Hsp90 protein complex: a possible mechanism to inhibit glioblastoma by geldanamycin. Cancer Res. 61 4010 PMID: 11358819
Wang et al (2011) Protection of murine neural progenitor cells by the Hsp90 inhibitor 17-allylamino-17-demethoxygeldanamycin in the low nanomolar concentration range. J.Neurochem. 117 703 PMID: 21395580
If you know of a relevant reference for 17-AAG, please let us know.
View Related Products by Product Action
Keywords: 17-AAG, supplier, Selective, Hsp90, inhibitors, inhibits, Heat, Shock, Protein, 90, NSC330507, antibiotics, stem, cells, protects, neural, progenitors, neuorprogenitors, stress-induced, apoptosis, Geldanamycin, NSC, 330507, 17-(Allylamino)-17-demethoxygeldanamycin, Tanespimycin, Hsp90, Antibiotics, Stem, Cell, Signaling, Hsp90, Tocris Bioscience
1 Citation for 17-AAG
Citations are publications that use Tocris products. Selected citations for 17-AAG include:
Hughes et al (2012) Pertuzumab Increases 17-AAG-Induced Degradation of ErbB2, and This Effect Is Further Increased by Combining Pertuzumab with Trastuzumab. Pharmaceuticals (Basel) 5 674 PMID: 24281706
Do you know of a great paper that uses 17-AAG from Tocris? If so please let us know.
Reviews for 17-AAG
There are currently no reviews for this product. Be the first to review 17-AAG and earn rewards!
Have you used 17-AAG?
Submit a review and receive an Amazon gift card.
$10US/$10CAN/€7/£6 gift card for a review without an image
$25US/$25CAN/€18/£15 gift card for a review with an image
*Offer only valid in the USA / Canada, UK and EuropeSubmit a Review
Literature in this Area
Parkinson's disease (PD) causes chronic disability and is the second most common neurodegenerative condition. This poster outlines the neurobiology of the disease, as well as highlighting current therapeutic treatments for symptomatic PD, and emerging therapeutic strategies to delay PD onset and progression.